Page 67 - Read Online

Bibi et al. J Transl Genet Genom 2024;8:119-161 https://dx.doi.org/10.20517/jtgg.2023.50 Page 157

2003;3:10. PubMed
175. Karbach J, Neumann A, Atmaca A, et al. Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in
antigen naive prostate cancer patients. Clin Cancer Res 2011;17:861-70. DOI
176. Guise TA. Parathyroid hormone related protein and bone metastases. Cancer 1997;80:1572-80. DOI PubMed
177. Arima Y, Matsueda S, Yano H, Harada M, Itoh K. Parathyroid hormone-related protein as a common target molecule in specific
immunotherapy for a wide variety of tumor types. Int J Oncol 2005;27:981-8. DOI PubMed
178. Edwards CM, Johnson RW. From good to bad: the opposing effects of PTHrP on tumor growth, dormancy, and metastasis throughout
cancer progression. Front Oncol 2021;11:644303. DOI PubMed PMC
179. Asadi F, Kukreja S. Parathyroid hormone-related protein in prostate cancer. Crit Rev Eukaryot Gene Expr 2005;15:15-28. DOI
PubMed
180. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science
1994;266:2011-5. DOI
181. Adotévi O, Mollier K, Neuveut C, et al. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse
transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 2006;12:3158-67. DOI
182. Negrini S, De Palma R, Filaci G. Anti-cancer immunotherapies targeting telomerase. Cancers 2020;12:2260. DOI PubMed PMC
183. Huo LF, Tang JW, Huang JJ, et al. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol
2006;3:1-11. PubMed
184. Leão R, Apolónio JD, Lee D, Figueiredo A, Tabori U, Castelo-Branco P. Mechanisms of human telomerase reverse transcriptase
(hTERT) regulation: clinical impacts in cancer. J Biomed Sci 2018;25:22. DOI PubMed PMC
185. Esquenazi Y, Ballester LY. Telomerase reverse transcriptase alterations in human cancers: diagnosis, prognosis, and therapeutic
implications. Cancer Cytopathol 2019;127:275-7. DOI PubMed
186. Yang R, Han Y, Guan X, et al. Regulation and clinical potential of telomerase reverse transcriptase (TERT/hTERT) in breast cancer.
Cell Commun Signal 2023;21:218. DOI PubMed PMC
187. Ryan BM, O’Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009;35:553-62. DOI
PubMed
188. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Oncogene 2005;24:2474-82. DOI PubMed
189. Xiang R, Mizutani N, Luo Y, et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung
tumor eradication. Cancer Res 2005;65:553-61. DOI
190. Ciesielski MJ, Kozbor D, Castanaro CA, Barone TA, Fenstermaker RA. Therapeutic effect of a T helper cell supported CTL response
induced by a survivin peptide vaccine against murine cerebral glioma. Cancer Immunol Immunother 2008;57:1827-35. DOI
PubMed PMC
191. Li F, Aljahdali I, Ling X. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? J
Exp Clin Cancer Res 2019;38:368. DOI PubMed PMC
192. Garg H, Suri P, Gupta JC, Talwar GP, Dubey S. Survivin: a unique target for tumor therapy. Cancer Cell Int 2016;16:49. DOI
PubMed PMC
193. Di Lorenzo G, Autorino R, De Laurentiis M, et al. HER-2/neu receptor in prostate cancer development and progression to androgen
independence. Tumori 2004;90:163-70. DOI
194. Neto AS, Tobias-Machado M, Wroclawski ML, et al. Her-2/neu expression in prostate adenocarcinoma: a systematic review and
meta-analysis. J Urol 2010;184:842-50. DOI
195. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy
2010;2:213-26. DOI PubMed
196. Agus DB, Scher HI, Higgins B, et al. Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -
independent human xenograft models. Cancer Res 1999;59:4761-4. PubMed
197. Formento P, Hannoun-Levi JM, Gérard F, et al. Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
Eur J Cancer 2005;41:1467-73. DOI
198. Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
J Clin Invest 2004;114:1774-81. DOI PubMed PMC
199. De Muga S, Hernández S, Agell L, et al. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade
and advanced-stage carcinomas. Mod Pathol 2010;23:703-12. DOI
200. Filho PA, López-Albaitero A, Gooding W, Ferris RL. Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-
specific T-cell epitope in head and neck cancer patients. J Immunother 2010;33:83-91. DOI PubMed PMC
201. Vexler A, Lidawi G, Loew V, et al. Anti-ErbB4 targeting approaches for prostate cancer treatment. Cancer Biol Ther 2008;7:1090-4.
DOI
202. Richards L. Genetics: N-cadherin - a target for prostate cancer therapy. Nat Rev Clin Oncol 2011;8:63. DOI PubMed
203. Tanaka H, Kono E, Tran CP, et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and
castration resistance. Nat Med 2010;16:1414-20. DOI PubMed PMC
204. Cui Y, Yamada S. N-cadherin dependent collective cell invasion of prostate cancer cells is regulated by the N-terminus of α-catenin.
PLoS One 2013;8:e55069. DOI PubMed PMC